The Moyamoya Disease disease mechanism overview
Moyamoya disease is a rare, progressive cerebrovascular disorder characterized by the narrowing or occlusion of arteries at the base of the brain, particularly the terminal portions of the internal carotid arteries and their main branches. As these main arteries progressively constrict, the brain attempts to compensate by forming a network of tiny, fragile blood vessels—giving a characteristic “puff of smoke” appearance on angiographic imaging, which is what “moyamoya” translates to in Japanese. Understanding the disease mechanism involves exploring both the vascular changes and the underlying pathological processes that lead to these alterations.
The initial event in moyamoya disease involves a gradual stenosis or narrowing of the distal internal carotid arteries and the proximal segments of the anterior and middle cerebral arteries. The precise cause of this narrowing remains unclear, but it is believed to involve a combination of genetic, environmental, and possibly autoimmune factors. Histopathological studies reveal that affected arteries exhibit proliferation of smooth muscle cells, thickening of the intimal layer, and destruction of the elastic lamina. These changes lead to a progressive reduction in luminal diameter, impairing blood flow to critical areas of the brain.
As these primary arteries become obstructed, cerebral blood flow diminishes, especially in the regions supplied by the affected arteries. To compensate for the reduced perfusion, the brain stimulates the development of collateral circulation. This process entails the formation of tiny, fragile vessels that attempt to bypass the stenosed arteries. These collateral vessels originate from different sources, such as the leptomeningeal anastomoses from the external carotid system and transdural collateral vessels. While these compensatory networks temporarily maintain cerebral perfusion, they are structurally weak and prone to rupture, which can lead to hemorrhagic strokes.
The abnormal vascular remodeling seen in moyamoya disease is driven by complex molecular and cellular mechanisms. Increased expression of angiogenic factors like vascular endothelial growth factor (VEGF) plays a key role in promoting neovascularization. However, this process is dysregulated, resulting in the proliferation of fragile vessels rather than stable, functional arteries. Additionally, inflammation and oxidative stress may contribute to the pathological changes observed in the vessel walls.
The disease process often results in a fluctuating clinical course, with patients experiencing ischemic strokes or transient ischemic attacks due to insufficient blood flow, especially during episodes of increased metabolic demand or hypotension. Conversely, the fragility of the newly formed vessels predisposes to hemorrhagic strokes, which are common in adult patients with moyamoya disease.
In summary, moyamoya disease involves a complex interplay of progressive arterial stenosis, pathological vessel wall changes, and the development of abnormal collateral networks. Its mechanism underscores the importance of early detection and intervention, as the fragile collateral vessels can both compensate for reduced blood flow and pose a risk of hemorrhage. Ongoing research aims to better understand the molecular underpinnings of this disorder to develop targeted therapies that can prevent or reverse the vascular changes.